Imprimis Pharmaceuticals Stock Working Capital
Imprimis Pharmaceuticals fundamentals help investors to digest information that contributes to Imprimis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Imprimis Stock. The fundamental analysis module provides a way to measure Imprimis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imprimis Pharmaceuticals stock.
Imprimis |
Imprimis Pharmaceuticals Company Working Capital Analysis
Imprimis Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Imprimis Pharmaceuticals Working Capital | 499 K |
Most of Imprimis Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imprimis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Imprimis Pharmaceuticals has a Working Capital of 499 K. This is 99.88% lower than that of the sector and 99.89% lower than that of the Working Capital industry. The working capital for all United States stocks is 99.97% higher than that of the company.
Imprimis Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imprimis Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imprimis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Imprimis Pharmaceuticals by comparing valuation metrics of similar companies.Imprimis Pharmaceuticals is currently under evaluation in working capital category among related companies.
Imprimis Fundamentals
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 | |||
| Profit Margin | (16.81) % | |||
| Operating Margin | (13.94) % | |||
| Current Valuation | 120.54 M | |||
| Shares Outstanding | 23.28 M | |||
| Shares Owned By Insiders | 7.16 % | |||
| Shares Owned By Institutions | 23.26 % | |||
| Number Of Shares Shorted | 231.01 K | |||
| Price To Earning | (2.02) X | |||
| Price To Book | 23.40 X | |||
| Price To Sales | 2.88 X | |||
| Revenue | 37.33 M | |||
| Gross Profit | 13.27 M | |||
| EBITDA | (3.35 M) | |||
| Net Income | (6.28 M) | |||
| Cash And Equivalents | 6.24 M | |||
| Cash Per Share | 0.27 X | |||
| Total Debt | 15.28 M | |||
| Debt To Equity | 343.10 % | |||
| Current Ratio | 1.13 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | 429 K | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (0.30) X | |||
| Price To Earnings To Growth | (0.13) X | |||
| Number Of Employees | 128 | |||
| Beta | -0.5 | |||
| Market Capitalization | 132.45 M | |||
| Total Asset | 14.13 M | |||
| Retained Earnings | (57.76 M) | |||
| Working Capital | 499 K | |||
| Current Asset | 5.87 M | |||
| Current Liabilities | 5.37 M | |||
| Z Score | 1.2 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Imprimis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Imprimis Pharmaceuticals' short interest history, or implied volatility extrapolated from Imprimis Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |